Leukaemia

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase II trial data for talquetamab, the company presented promising findings on the long-term results […]

Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML). The investments include €3.6 million committed by Oost NL and a select number of private investors, […]

The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more TKI therapies. Scemblix is the […]

This poster by Levitas Bio provides a useful guide for leukaemia researchers wanting to use scRNAseq and analysis to uncover new data points. Download the Poster to discover more about: scRNAseq and analysis with enriched, purified cells leads to better data, often uncovering data points that may be obscured by dead cells and debris Engraftment in […]

Biopharmaceutical company Nurix Therapeutics has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of its lead drug candidate targeting relapsed or refractory B-cell malignancies  The company’s lead candidate, NX-2127, is an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity. Nurix had initially launched NX-2127 […]